检索结果-南通市图书馆

The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DrD2/ANKK (Taq1A)), OPrM1 (A/G), DrD3 (C/T), and MAOA (4r) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine regulation (KB220) and Antibacterial Therapies

引用

Open Journal of Immunology 2024年第3期14卷 60-86页

作者： Kenneth Blum Igor Elman David Han Colin Hanna David Baron Ashim Gupta Shan Kazmi Jag Khalsa Debasis Bagchi Thomas McLaughlin rajendra D. Badgaiyan Edward J. Modestino Drew Edwards Catherine A. Dennen eric.r. braverman Abdalla Bowirrat Keerthy Sunder Kevin Murphy Nicole Jafari Foojan Zeine Paul r. Carney Mark S. Gold Kai-Uwe Lewandowski Alireza Sharafshah Aryeh r. Pollack Panayotis K. Thanos Division of Addiction research & Education Center for Sports and Mental Health Western University of Health Sciences Pomona CA USA Department of Psychiatry Boonshoft School of Medicine Wright State University and Dayton VA Medical Centre Dayton OH USA Division of Nutrigenomics Victory Nutrition International Lederoch PA USA Institute of Psychology ELTE Etvs Lornd University Budapest Hungary Department of Psychiatry School of Medicine University of Vermont Burlington VT USA The Kenneth Blum Behavioral & Neurogenetic Institute LLC. Austin TX USA Department of Molecular Biology Adelson School of Medicine Ariel University Ariel Israel Division of Neuromodulation research Karma Doctors & Karma TMS Palm Springs CA USA Division of Personalized Interventions Peak Logic Del Mar CA USA Division of Personalized Medicine Cross-Cultural Research & Educational Institute San Clemente CA USA Awareness Integration Institute San Clemente CA USA Division of Personalized Pain Therapy Center for Advanced Spine Care of Southern Arizona Tucson AZ USA Department of Psychiatry Harvard School of Medicine Cambridge MA USA Department of Management Science and Statistics University of Texas San Antonio TX USA Behavioral Neuropharmacology and Neuroimaging Laboratory Clinical Research Institute on Addictions Department of Pharmacology and Toxicology Jacobs School of Medicine and Biomedical Sciences University at Buffalo Buffalo NY USA Future Biologics Lawrenceville GA USA Department of Microbiology Immunology & Tropic Diseases School of Medicine Georgetown University Washington DC USA Department of Pharmaceutical Sciences College of Pharmacy Texas Southern University Houston TX USA Department of Psychiatry School of Medicine Case Western University Cleveland OH USA Brain and Behavior Laboratory Curry College Milton MA USA The Neurogenesis Project Jacksonville FL USA Department of Family Medicine Jefferson Health Northeast Philadelphia PA USA Departmen

Pediatric autoimmune neuropsychiatric disorders associated with or without streptococcal and other bacterial infections (PANDAS/CANS) are emerging as a featured pediatric disorder. Although there is some controversy regarding treatment approaches, especially related to the behavioral sequelae, we have hypothesized in other published work that it is characterized by the rapid onset of reward Deficiency Syndrome (rDS) in children. We propose utilizing a multi-systems biological approach involving the coupling of genetic addiction risk testing and pro-dopamine regulation (KB220/POLYGEN®) to help induce “dopamine homeostasis” in patients with PANDAS, especially those with known DNA-induced hypodopaminergia. This case study examines a 12-year-old Caucasian male with no prior psychiatric issues who presented with a sudden onset of severe anxiety, depression, emotional liability, and suicidal ideation. The patient underwent genotyping and the genetic addiction risk score (GArS) testing, which revealed risk polymorphisms in the dopamine D2 (-DrD2/ANKK (Taq1A), OPrM1 (A/G), DrD3 (C/T), and MAOA (4r) genes. These polymorphisms have been linked to hypodopaminergia. The patient was subsequently placed on research ID-KB220ZPBMPOLY (POLYGEN®), and albeit the possibility of bias, based upon self and parental assessment, a marked rapid improvement in psychiatric symptoms was observed. In the second phase of treatment (102 days utilizing KB220), the patient received standard antibody testing, which was positive for Lyme. Antibacterial therapy started immediately, and KB220z was discontinued to provide a wash-out period. A monotonic trend analysis was performed on each outcome measure, and a consistently decreasing trend was observed utilizing antibacterial therapy. Our recommendation, albeit only one case, is to utilize and further research a combined therapeutic approach, involving precision-guided DNA testing and pro-dopamine regulation along with antibacterial therapy, as well as

关键词： PANDAS CANS Genetic Addiction risk Testing (GArS) Pro-Dopamine regulation Hypodopaminergia Polymorphisms Antibacterial Therapy Infections

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Understanding that Addiction Is a Brain Disorder Offers Help and Hope

引用

Health 2022年第6期14卷 684-695页

作者： Kenneth Blum Abdalla Bowirrat David Baron rajendra D. Badgaiyan Panayotis K. Thanos Igor Elman eric.r. braverman Mark S. Gold Division of Addiction research & Education Center for Psychiatry Medicine & Primary Care (Office of the Provost) Western University Health Sciences Pomona USA Department of Molecular Biology and Adelson School of Medicine Ariel University Ariel Israel Department of Psychiatry South Texas Veteran Health Care System Audie L. Murphy Memorial VA Hospital and Long School of Medicine University of Texas Health Science Center San Antonio USA Department of Psychiatry MT. Sinai School of Medicine New York USA Department of Psychology & Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA) Research Institute on Addictions University at Buffalo Buffalo USA Department of Psychiatry Harvard School of Medicine Cambridge USA Division of Personalized Medicine The Kenneth Blum Behavioral & Neurogenetic Institute (Division of iVitalize Inc.) Austin USA Department of Psychiatry Washington University School of Medicine St. Louis USA

We refute the controversial statement that addiction is not a brain disorder. Extensive peer-reviewed studies support the underlying neurobiological and neurogenetic basis of addiction’s “disease model”. In the 70s and 80s, a few clinical scientists suggested that it is possible to use behavioral training to teach controlled drinking. However, this controversial model failed drastically and increased labeling and stigmatization. Additionally, it was unhelpful in the search for treatment. Instead, we assert that addiction is a neuropsychiatric disorder characterized by a recurring desire to continue taking substances despite harmful physical and mental consequences. Work from our laboratory in 1995 supported the reward Deficiency Syndrome (rDS) concept based on a common neurogenetic mechanism (hypodopaminergia) that underlies all substance and non-substance addictions. Non-substance addictions include behaviors like pathological gambling, internet addiction, and mobile phone addiction. Certain impulsive and compulsive behaviors or the acute intake of psychoactive substances result in heightened dopaminergic activity, while the opposite, hypodopaminergia, occurs following chronic abuse. Patients with Substance Use Disorder (SUD) can have a genetic predisposition compounded by stress or other epigenetic insults that can impact recovery. relapse will occur post-short-term recovery if dopaminergic dysfunction remains untreated. Addiction, a brain disorder, requires treatment with DNA-directed pro-dopamine regulation and rehabilitation.

关键词： reward Deficiency Syndrome Abstinence Controlled Drinking Neurogenetic Brain Disorder

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hypothesizing “reward” Gene Polymorphisms May Predict High rates of Injury and Addiction in the Workforce: A Nutrient and Electrotherapeutic Based Solution

引用

Health 2014年第16期6卷 2261-2285页

作者： Kenneth Blum Thomas Simpaatico roger L. Waite Seth H. Blum Kristina Dushaj Margaret A. Madigan eric.r. braverman Marlene Oscar-Bermanm Department of Psychiatry and McKnight Brain Institute University of Florida College of Medicine Gainesville USA Department of Nutrigenomic research RDSolutions LLC Del Mar USA Department of Neurology PATH Foundation NY New York USA Dominion Diagnostics LLC North Kingstown USA Department of Psychiatry Human Integrated Services Unit University of Vermont Center for Clinical & Translational Science College of Medicine Burlington USA Department of Genomics IGENE LLC Austin USA Department of Addiction research & Therapy Malibu Beach Recovery Center Malibu Beach USA Departments of Psychiatry Neurology and Anatomy & Neurobiology Boston University School of Medicine and Boston VA Healthcare System Boston USA

We hypothesize that individuals with genetic predisposition to Substance Use Disorder (SUD) may have greater likelihood of experiencing work related accidents. We further hypothesize that high risk populations will carry single or multiple polymorphisms associated with brain reward circuitry and/or brain reward cascade, including: Dopaminergic (i.e. DrD2 receptor genes);Serotonergic (i.e. 5-HTT2 receptor genes);Endorphinergic (i.e. pre-enkephalin genes);Gabergic (i.e. GABAA receptor genes);Neurotransmitter Metabolizing genes (i.e. MAO and COMT genes) among others (GArSrXTM). Analgesic addiction as well as “pseudoaddiction” must be treated to improve pain control and its management. We propose that non-pharmacological alternatives to pain relief, in high risk, addiction-prone individuals, are Electrotherapeutic Device(s) and Programs. We further propose patented KB220Z, a nutraceutical designed to release dopamine at the nucleus accumbens, will reduce craving behavior, in genetically programmed individuals. By utilizing both alternatives in DNA analyzed injured workers, a reduction in analgesic addiction (genuine or pseudo) leads to improved health and quicker return to work. We also hypothesize that this novel approach will impact costs related to injuries in the workforce. Effective management of chronic pain, especially in high addiction-prone workforce populations, is possible in spite of being particularly elusive. A series of factors encumber pain assessment and management, including analgesia addiction, pharmacogenomic response to pain medications, and genetically inherited factors involving gene polymorphisms. Additional research is required to test these stipulated hypotheses related to genetic proneness to addiction, but also proneness to accidents in the workplace and reduction of craving behavior. Our hypothesis that genotyping coupled with both KB220ZTM and the pharmaceutical-free Electrotherapy, will reduce iatrogenic induced analgesia addiction. This a

关键词： Injuries Workforce reward Gene Polymorphisms KB220Z Electrotherapy Device & Program Iatrogenic Analgesic Addiction reward Deficiency System Solution

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes rapid Onset of reward Deficiency Syndrome (rDS) Behaviors and May require Induction of “Dopamine Homeostasis”

引用

Open Journal of Immunology 2022年第3期12卷 65-75页

作者： Kenneth Blum Catherine A. Dennen eric.r. braverman Ashim Gupta David Baron Bernard William Downs Debasis Bagchi Panayotis Thanos Maureen Pollock Jag Khalsa Igor Elman Abdalla Bowirrat rajendra D. Badgaiyan Center for Mental Health and Sports Psychiatry Western University Health Sciences Pomona USA The Kenneth Blum Behavioral & Neurogenetic Institute Austin USA Department Psychiatry Boonshoff School of Medicine Wright University Dayton USA Institute of Psychology ELTE E&#246tv&#246s Loránd University Budapest Hungary Department of Psychiatry School of Medicine University of Vermont Burlington USA Division of Nutrigenomics Victory Nutrition International Inc. Bonita Springs USA Department of Molecular Biology Adelson School of Medicine Ariel University Ariel Israel Department of Family Medicine Jefferson Health Northeast Philadelphia USA Future Biologics Lawrenceville USA Department of Pharmaceutical Sciences Texas Southern University Houston USA Department of Psychology & Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA) Research Institute on Addictions University at Buffalo Buffalo USA Department of Microbiology Immunology and Tropical Medicine School of Medicine George Washington University Washington DC USA Cambridge Health Alliance Harvard Medical School Cambridge USA Department of Psychiatry Ichan School of Medicine at Mount Sinai New York USA Department of Psychiatry South Texas Veteran Health Care System Audie L. Murphy Memorial VA Hospital Long School of Medicine University of Texas Health Science Center San Antonio USA

Pediatric autoimmune neuropsychiatric disorders associated with group A streptococcal infections (PANDAS) is a concept that is used to characterize a subset of children with neuropsychiatric symptoms, tic disorders, or obsessive-compulsive disorder (OCD), whose symptoms are exacerbated by group A streptococcal (GAS) infection. PANDAS has been known to cause a sudden onset of reward deficiency syndrome (rDS). rDS includes multiple disorders that are characterized by dopaminergic signaling dysfunction in the brain reward cascade (BrC), which may result in addiction, depression, avoidant behaviors, anxiety, tic disorders, and/or OCD. According to research by Blum et al., the dopamine receptor D2 (DrD2) gene polymorphisms are important prevalent genetic determinants of rDS. The literature demonstrates that infections like Borrelia and Lyme, as well as other infections like group A beta-hemolytic streptococcal (GABHS), can cause an autoimmune reaction and associated antibodies target dopaminergic loci in the mesolimbic region of the brain, which interferes with brain function and potentially causes rDS-like symptoms/behaviors. The treatment of PANDAS remains controversial, especially since there have been limited efficacy studies to date. We propose an innovative potential treatment for PANDAS based on previous clinical trials using a pro-dopamine regulator known as KB220 variants. Our ongoing research suggests that achieving “dopamine homeostasis” by precision-guided DNA testing and pro-dopamine modulation could result in improved therapeutic outcomes.

关键词： PANDAS CANS reward Deficiency Syndrome Group A Beta-Hemolytic Streptococcal (GABHS) Pro-Dopamine regulation Dopamine Homeostasis Molecular Mimicry Lyme Borrelia

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Iatrogenic opioid dependence is endemic and legal: Genetic addiction risk score (GArS) with electrotherapy a paradigm shift in pain treatment programs

引用

Health 2013年第11期5卷 16-34页

作者： Kenneth Blum David Han Marlene Oscar-Berman Gary reinl Nicholas DiNubile Margaret A. Madigan Anish Bajaj Bernard William Downs John Giordano Wayne Westcott Leonard Smith eric.r. braverman Kristina Dushaj Mary Hauser Thomas Simpatico Thomas McLaughlin Joan Borsten Debmayla Barh Center for Psychiatric Medicine North Andover USA Centre for Genomics and Applied Gene Technology Institute of Integrative Omics and Applied Biotechnology (IIOAB) Nonakuri Purba Medinipur India Department of Addiction research & Therapy Malibu Beach Recovery Center Malibu Beach USA Department of Executive Health Path Research Foundation NY New York USA Department of Exercise Science Quincy College Quincy USA Department of Holistic Medicine and Pain Track National Institute for Holistic Addiction Studies North Miami Beach USA Department of Management Science and Statistics The University of Texas at San Antonio San Antonio USA Department of Molecular Nutrition Impact Genomics Inc. Austin USA Igene LLC Austin USA Department of Psychiatry Anatomy & Neurobiology Boston VA and Boston University School of Medicine Boston USA Department of Psychiatry College of Medicine & McKnight Brain Institute University of Florida Gainesville USA Department of Executive Health Path Research Foundation NY New York USA Department of Psychiatry College of Medicine & McKnight Brain Institute University of Florida Gainesville USA Electronic Waveform Lab Department of Pain Research Huntington Beach USA Department of Orthopedic Surgery Hospital of the University of Pennsylvania Philadelphia USA Department of Molecular Nutrition Impact Genomics Inc. Austin USA Department of Executive Health Path Research Foundation NY New York USA Department of Holistic Medicine and Pain Track National Institute for Holistic Addiction Studies North Miami Beach USA Dominion Diagnostics LLC North Kingstown USA Department of Psychiatry Human Integrated Services Unit of Vermont Center for Clinical & Translational Science University of Vermont College of Medicine Burlington USA Department of Addiction Research & Therapy Malibu Beach Recovery Center Malibu Beach USA Centre for Genomics and Applied Gene Technology Institute of Integrative Omics and Applied Biotechnology (IIOAB) Nonakuri Purba Me

The mounting endemic of prescription iatrogenic opioid dependence in pain patients provoked this treatise about an alternative method that can be used to treat pain, improve function and reduce the risk of opioid dependence. It is well known that as well as the side effects reported for chronic opioid therapy, genetically predisposed individuals are at risk for opioid dependence. We propose the use of the Genetic Addiction risk Score (GArS) assessment to identify patients early in treatment who should avoid narcotic pain medications. Primarily, this review will be an exploration of the mechanisms of action of an electrotherapeutic alternative to narcotic treatment that can be used to augment tissue healing and reduce the pain associated with human injuries and neuropathies. This particular electrotherapeutic device was developed at the Electronic Waveform Laboratory in Huntington Beach, California and is called the H-Wave? device. The primary effect of the H-Wave?device is stimulation (HWDS) of small diameter fibers of “red-slow-twitch” skeletal muscle. Mechanisms of action of HWDS have been investigated in both animal and human studies. They include edema reduction, induction of nitric oxide dependent augmented microcirculation and angiogenesis, small muscle contraction that eliminates transcapillary fluid shifts, reducing the painful effects of tetanizing fatigue and gradual loading of healing injured muscle tissue that helps repair and remodeling. A recent metaanalysis found a moderate-to-strong-positive effect of the HWDS in providing pain relief, reducing the requirement for pain medication, with the most robust effect being increased functionality. We are proposing that GArS can be used to identify those at risk of developing opioid dependence and that the need for opioid analgesia can be reduced by use of this electro therapeutic alternative to opioid analgesia in the treatment of pain and injuries.

关键词： Microcirculation Angiogenesis Analgesic Therapy Electrical Device Stimulation Tissue Loading remodeling Genetic Addiction risk Score (GArS) reward Deficiency Syndrome (rDS)

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

引用

Open Journal of Immunology（免疫学期刊） 2022年第3期

作者： kenneth blum catherine a. dennen eric.r. braverman ashim gupta david baron bernard william downs debasis bagchi panayotis thanos maureen pollock jag khalsa igor elman abdalla bowirrat rajendra d. badgaiyan

来源：博看期刊评论

在线全文

博看期刊

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：